Patents by Inventor Kenji Sudo
Kenji Sudo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9463236Abstract: A composition comprising the following composition: an AD vehicle including a synthetic peptide and a lipid, wherein the synthetic peptide includes the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20), a carboxylvinyl polymer and an RSV antigen. The composition has an antibody producing ability which is further higher than that of a conventional mucosal vaccine, hence capable of exerting excellent anti-virus antigen-specific IgA antibody- and IgG antibody-inducing effect in the nasal wash and the serum, respectively, even with an extremely small quantity of an RSV antigen.Type: GrantFiled: August 29, 2012Date of Patent: October 11, 2016Assignee: TOKUSHIMA UNIVERSITYInventors: Hiroshi Kido, Dai Mizuno, Hirotsugu Ueda, Koji Yoshikawa, Keisuke Ohsumi, Nobuyuki Yamamoto, Kenji Sudo
-
Publication number: 20150297713Abstract: A composition comprising the following composition: an AD vehicle including a synthetic peptide and a lipid, wherein the synthetic peptide includes the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20), a carboxylvinyl polymer and an RSV antigen. The composition has an antibody producing ability which is further higher than that of a conventional mucosal vaccine, hence capable of exerting excellent anti-virus antigen-specific IgA antibody- and IgG antibody-inducing effect in the nasal wash and the serum, respectively, even with an extremely small quantity of an RSV antigen.Type: ApplicationFiled: August 29, 2012Publication date: October 22, 2015Inventors: Hiroshi KIDO, Dai MIZUNO, Hirotsugu UEDA, Koji YOSHIKAWA, Keisuke OHSUMI, Nobuyaki YAMAMOTO, Kenji SUDO
-
Patent number: 8125963Abstract: A radio communication method and apparatus generate a plurality of information signals and transmit the signals to a communication partner from a plurality of antennas. A plurality of combination of signals to be transmitted are selected. A transmission evaluation value is determined based on the signal noise ratio of each signal. After all combinations are evaluated, a transmission format suitable for sending a combination of signals is determined based on a highest evaluation value.Type: GrantFiled: July 29, 2004Date of Patent: February 28, 2012Assignee: Mitsubishi Denki Kabushiki KaishaInventors: Yoshitaka Hara, Akinori Taira, Tomoaki Otsuki, Kenji Sudo
-
Publication number: 20090048310Abstract: [Problems] To provide an agent useful for the prevention or treatment of various diseases associated with the infection with acyclovir-resistant viruses of the family Herpesviridae, specifically various infectious caused by herpes viruses, such as varicella associated with varicella-zoster virus infection, herpes zoster associated with recurrent infection with latent varicella-zoster virus, and herpes labialis, herpes encephalitis and genital herpes associated with HSV-1 and HSV-2 infection, and the like. [Means for Solving Problems] An N-[2-[(4-substituted phenyl)amino]-2-oxoethyl]tetrahydro-2H-thiopyran-4-carboxamide derivative in which the phenyl group is substituted at position 4 by a specific 5- or 6-membered heteroaryl group. This derivative has an excellent anti-viral activity against acyclovir-resistant herpes viruses and, therefore, is effective for the treatment of the diseases as mentioned above.Type: ApplicationFiled: February 1, 2006Publication date: February 19, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Hiroshi Suzuki, Koji Chono, Kenji Sudo
-
Publication number: 20090042915Abstract: [Problems] To provide a medicament, particularly a pharmaceutical composition useful for preventing or treating a variety of diseases caused by infection of a virus of the Herpesviridae family. [Means for Solving Problems] The present invention relates to an anti-herpesvirus agent characterized by combining a helicase-primase inhibitor with a polymerase inhibitor. By combining the polymerase inhibitor with the helicase-primase inhibitor having different functional mechanisms, the anti-herpesvirus agent of the present invention achieves an extremely superior anti-herpesvirus activity compared with conventional administration of a polymerase inhibitor alone. Therefore, it is particularly effective in a case in which a sufficient therapeutic effect cannot be achieved only with a polymerase inhibitor. Further, since the doses of both agents can be kept low, it is also possible to perform treatment by lowering the effect of an adverse reaction to be concerned.Type: ApplicationFiled: February 1, 2006Publication date: February 12, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Hiroshi Suzuki, Kenji Sudo
-
Publication number: 20090030049Abstract: [PROBLEMS] To provide a medicament useful for the treatment of genital herpes after the development of lesions. [MEANS FOR SOLVING PROBLEMS] An N-[2-[(4-substituted phenyl)amino]-2-oxoethyl]tetrahydro-2H-thiopyran-4-carboxamide derivative in which the phenyl group is substituted at position 4 by a specific 5- or 6-membered heteroaryl group has an excellent anti-herpesvirus effect and can exert excellent therapeutic effect on genital herpes after the development of lesions. Therefore, the compound is useful for the treatment of genital herpes after the development of lesions.Type: ApplicationFiled: February 1, 2006Publication date: January 29, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Hiroshi Suzuki, Kenji Sudo
-
Patent number: 7465748Abstract: There is provided a pharmaceutical drug, particularly a novel compound useful for prophylaxis or a therapeutic treatment of various diseases involving infections with viruses of the herpesvirus family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. An N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative, of which phenyl group is substituted at position 4 with a specific 5- or 6-membered heteroaryl group, and a salt thereof have an effective anti-virus activity, and the oral administration thereof at a low dose enabled the therapeutic treatment of the above diseases.Type: GrantFiled: August 5, 2004Date of Patent: December 16, 2008Assignees: Astellas Pharma Inc., Rational Drug Design LaboratoriesInventors: Toru Kontani, Junji Miyata, Wataru Hamaguchi, Tomoaki Kawano, Akio Kamikawa, Hiroshi Suzuki, Kenji Sudo
-
Publication number: 20060229295Abstract: There is provided a pharmaceutical drug, particularly a novel compound useful for prophylaxis or a therapeutic treatment of various diseases involving infections with viruses of the herpesvirus family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. An N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative, of which phenyl group is substituted at position 4 with a specific 5- or 6-membered heteroaryl group, and a salt thereof have an effective anti-virus activity, and the oral administration thereof at a low dose enabled the therapeutic treatment of the above diseases.Type: ApplicationFiled: August 5, 2004Publication date: October 12, 2006Applicant: Astellas Pharma Inc.and Rational Drug DesignInventors: Toru Kontani, Junji Miyata, Wataru Hamaguchi, Tomoaki Kawano, Akio Kamikawa, Hiroshi Suzuki, Kenji Sudo
-
Patent number: 6903125Abstract: A pharmaceutical drug, particularly a novel compound useful for the prophylaxis or therapeutic treatment of various diseases involving infections with viruses of the Herpesviridae family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. N-{2-[(4-Substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative where the phenyl group is substituted at position 4 with a specific five-membered or 6-membered heteroaryl group, has such great anti-virus activity that the oral dosing thereof at a low dose enabled the therapeutic treatment of the diseases.Type: GrantFiled: August 6, 2004Date of Patent: June 7, 2005Assignees: Yamanouchi Pharmaceutical Co., Ltd., Rational Drug Design LaboratoriesInventors: Toru Kontani, Junji Miyata, Wataru Hamaguchi, Tomoaki Kawano, Akio Kamikawa, Hiroshi Suzuki, Kenji Sudo
-
Publication number: 20050032855Abstract: A pharmaceutical drug, particularly a novel compound useful for the prophylaxis or therapeutic treatment of various diseases involving infections with viruses of the Herpesviridae family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. N-{2-[(4-Substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative where the phenyl group is substituted at position 4 with a specific five-membered or 6-membered heteroaryl group, has such great anti-virus activity that the oral dosing thereof at a low dose enabled the therapeutic treatment of the diseases.Type: ApplicationFiled: August 6, 2004Publication date: February 10, 2005Inventors: Toru Kontani, Junji Miyata, Wataru Hamaguchi, Tomoaki Kawano, Akio Kamikawa, Hiroshi Suzuki, Kenji Sudo
-
Patent number: 5698580Abstract: Antiviral agents comprising, as an active ingredient, a 1,4-dihydro-2,3-benzodithiin derivative of the formula ##STR1## wherein each symbol is as defined in the Specification, or a pharmacologically acceptable salt thereof. The antiviral agents of the present invention have superior antiviral activity and are effective for the preventive and therapeutic treatment of viral diseases caused typically by RS virus.Type: GrantFiled: December 16, 1996Date of Patent: December 16, 1997Assignee: Rational Drug Design LaboratoriesInventors: Tsuyoshi Kajiyashiki, Ryu Sato, Tomoyuki Yokota, Kenji Sudo, Wataru Watanabe, Shiro Shigeta